In compliance with art L.5121-1-3 of French Public Health Code, please find hereunder the list of medicinal product for which OHRE Pharma is responsable for placing on the market :
- Bosentan OHRE Pharma 62,5 mg, tablet – SPC 26/01/2018
- Bosentan OHRE Pharma 125 mg, tablet – SPC 26/01/2018
- Caspofungine OHRE Pharma 50 mg, powder for concentrate for solution for infusion – SPC 16/03/2017
- Caspofungine OHRE Pharma 70 mg, powder for concentrate for solution for infusion – SPC 16/03/2017
- Linezolide OHRE Pharma 600 mg, tablet – SPC 12/09/2019
- Mémantine OHRE Pharma 10 mg/ml, oral solution – SPC 24/07/2019
- Posaconazole OHRE Pharma 40 mg/ml, oral suspension – SPC 11/09/2019
- Sildénafil OHRE Pharma 20 mg, tablet – SPC 09/02/2018
- Voriconazole OHRE Pharma 50 mg, tablet – SPC 19/04/2019
- Voriconazole OHRE Pharma 200 mg, tablet – SPC 19/04/2019
- Voriconazole OHRE Pharma 200 mg, powder for solution for injection – SPC 08/04/2019
For more information concerning our drugs, you can click to the following link: French medicinal product data base.
For Voriconazole and Bosentan Risk Management, OHRE Pharma laboratory provide medical information brochure (validated by the French National Medicines Agency) to patients and healthcare professionals:
For Bosentan OHRE Pharma:
- Patient brochure to provide to new patients Under treatment
- Patient synthesis to remind the need for adequate contraception and regular liver checks
- Healthcare Professional brochure for HTAP information
- Healthcare Professional brochure for Digital Ulceration information
For Voriconazole OHRE Pharma:
- Patient brochure focusing on the most important information in order to guarantee voriconazole safe use
- To see or download this booklet follow this link.
- Healthcare professional brochure with questions /answers and chek-list.
Last update realized in January 2020.